Business
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
Press Release Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories €7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 millionTiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere Kowa will assume full responsibility for the preparation and fi
About this update from Kowa Co. Ltd.
[{"type":"image","alt":"NICOX SA","displaySize":"","headline":null,"caption":"NICOX SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":177,"url":"https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rPuxYymeI_hpr5ShJmv9pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8","width":290,"height":177}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"3","style":"width:603px;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Press Release ","length":13,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"3","style":"width:603px;border-top:solid black 1pt;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories","length":150,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"3","style":"width:603px;vertical-align:top;","val":[{"type":"list","items":[{"val":[{"type":"text","content":"€7.5 million upfront, with total potential development and commercial milestones, depending on Denali trial results, of up to €191.5 million","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"Tiered royalties of up to 20% in the U.S., starting at a minimum of 8%, with tiered high single to double digit royalties elsewhere ","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Kowa will assume full responsibility for the preparation and filing costs of the U.S. NDA for NCX 470, and all future development and commercial costs","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"Provides flexibility for Nicox to explore future growth options","length":63,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":484,"olType":false},{"type":"text","content":"July 17, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the signing of a major new agreement concerning NCX 470 with Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-...